Dihydroboldenone
A non-aromatizing injectable anabolic steroid (DHT derivative of Boldenone). Provides lean, dry gains similar to Primobolan but with stronger anabolic potency. Known for severe post-injection pain (PIP). Very limited human clinical data exists.
Mechanism of Action
Binds androgen receptors directly — already 5α-reduced so no further reduction occurs. Does not aromatize into estrogen. Exhibits strong androgen receptor affinity and drives protein synthesis in skeletal muscle. Moderate erythropoiesis stimulation. The 1-dehydro modification increases anabolic selectivity over the parent Boldenone molecule.
Typical Dosing
⚠ Warning Flags
- •ZERO human clinical data — all evidence is preclinical or anecdotal
- •Notorious for severe post-injection pain (PIP)
- •Does not aromatize — requires a testosterone base for estrogen support
- •No estrogen = no neuroprotection or cardioprotection from this compound alone
Effect Profile
Side Effect Profile
Research Studies
Androgens and Anabolic Agents: Chemistry and Pharmacology
Vida JA · 1969
Classified 1-testosterone (DHB) as a highly anabolic compound with favorable tissue selectivity relative to testosterone.
Pharmacology of anabolic steroids
Kicman AT · 2008
Reviews structure-activity relationships of AAS including 1-dehydro modifications that increase anabolic selectivity.
Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities
Fragkaki AG et al. · 2009
Confirms strong androgen receptor binding affinity of 1-testosterone derivatives.